US5008240A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating inflammation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1988-08-09
•
Granted: 1991-04-16
•
Expires: 2008-08-09
Abstract
Abstract Inflammation, acute and/or chronic, is treated with a CIF (TGF- beta ). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration or activator or cofactor for efficacy.
Inventors
- 👤 Hanne Bentz
- 👤 Larry Ellingsworth
- 👤 Rosa Armstrong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 22:36
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61P; A61P29/00; A61P37/00; A61P7/00; C07K14/51; C07K16/00; C07K16/18; C07K16/22; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
104 words
A method of treating a patient for the alleviation of a symptom or manifestation of a disease resulting in inflammation comprising administering an anti-inflammatorily effective amount of a protein having the amino acid sequence of cartilage inducing factor A or B or TGF-β or a functional equivalent thereof to the patient wherein any functional equivalent is a substantially homologous protein with the cartilage inducing factor protein A or B or TGF-β and wherein differences in sequences between the cartilage inducing factor protein A or B or TGF-β and any substantially homologous protein does not affect the anti-inflammatory activity of the cartilage inducing factor adversely.
Claim 2
Independent Claim
104 words
A method of treating a patient for the alleviation of a symptom or manifestation of a disease resulting in inflammation comprising administering an anti-inflammatorily effective amount of a protein having the amino acid sequence of cartilage inducing factor A or B or TGF-β or a functional equivalent thereof to the patient wherein any functional equivalent is a substantially homologous protein with the cartilage inducing factor protein A or B or TGF-β and wherein differences in sequences between the cartilage inducing factor protein A or B or TGF-β and any substantially homologous protein does not affect the anti-inflammatory activity of the cartilage inducing factor adversely.
Claim 3
Dependent Claim
40 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is a homodimer whose chains do not have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp, or (b) The following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp-.
Claim 4
Dependent Claim
21 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is substantially free of activating agent or cofactor.
Claim 5
Dependent Claim
10 words
The method of claim 1 wherein the inflammation is acute.
Claim 6
Dependent Claim
10 words
The method of claim 1 wherein the inflammation is chronic.
Claim 7
Dependent Claim
16 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is administered systemically.
Claim 8
Dependent Claim
16 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is administered locally.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein the inflammation involves the respiratory system of the patient.
Claim 10
Dependent Claim
20 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is administered to the patient by inhalation.
Claim 11
Dependent Claim
11 words
The method of claim 1 wherein the inflammation is dermal inflammation.
Claim 12
Dependent Claim
16 words
The method of claim 1 wherein the cartilage inducing factor or functional equivalent is administered topically.
Claim 13
Dependent Claim
14 words
The method of claim 1 wherein the inflammation is associated with an autoimmune disease.
Claim 14
Dependent Claim
13 words
The method of claim 1 wherein the inflammation is in the gastrointestinal tract.
Claim 15
Dependent Claim
12 words
The method of claim 1 wherein said inflammation is due to arthritis.
Claim 16
Independent Claim
83 words
A method for suppressing the immune system of a mammal, which method comprises administering to a mammal suffering from rheumatoid arthritis an immunosuppressive amount of a cartilage inducing factor A or B or TGF-β or functional equivalent wherein any functional equivalent is a substantially homologous protein to cartilage inducing factor A or B or TGF-β and wherein any differences between cartilage inducing factor A or B or TFG-β and a functional equivalent does not affect the anti-inflammatory activity of the functional equivalent adversely.
Claim 17
Independent Claim
83 words
A method for suppressing the immune system of a mammal, which method comprises administering to a mammal suffering from rheumatoid arthritis an immunosuppressive amount of a cartilage inducing factor A or B or TGF-β or functional equivalent wherein any functional equivalent is a substantially homologous protein to cartilage inducing factor A or B or TGF-β and wherein any differences between cartilage inducing factor A or B or TFG-β and a functional equivalent does not affect the anti-inflammatory activity of the functional equivalent adversely.
Claim 18
Dependent Claim
39 words
The method of claim 15 wherein the cartilage inducing factor or functional equivalent is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 19
Dependent Claim
28 words
The method of claim 15 wherein the cartilage inducing factor or functional equivalent is a homodimer whose chains each have the amino acid sequence shown in FIG. 1.
Claim 20
Dependent Claim
21 words
The method of claim 15 wherein the cartilage inducing factor or functional equivalent is substantially free of activating agent or cofactor.
Claim 21
Independent Claim
125 words
A method of treating a patient for the alleviation of an inflammatory symptom or inflammatory manifestation of a disease selected from the group consisting of psoriasis, contact dermatitis, dermal ulcers, or eczema, comprising: topically administering an effective amount of a protein having the amino acid sequence of cartilage inducing factor A or B or TGF-β or a functional equivalent thereof to a patient having psoriasis, contact dermatitis, dermal ulcers or eczema wherein any functional equivalent is a protein having a substantially homologous amino acid sequence with the cartilage inducing factor protein A or B or TGF-β and wherein any difference between the amino acid sequence of cartilage inducing factor A or B or TGF-β and the functional equivalent does not affect the anti-inflammatory activity adversely.
Claim 22
Independent Claim
125 words
A method of treating a patient for the alleviation of an inflammatory symptom or inflammatory manifestation of a disease selected from the group consisting of psoriasis, contact dermatitis, dermal ulcers, or eczema, comprising: topically administering an effective amount of a protein having the amino acid sequence of cartilage inducing factor A or B or TGF-β or a functional equivalent thereof to a patient having psoriasis, contact dermatitis, dermal ulcers or eczema wherein any functional equivalent is a protein having a substantially homologous amino acid sequence with the cartilage inducing factor protein A or B or TGF-β and wherein any difference between the amino acid sequence of cartilage inducing factor A or B or TGF-β and the functional equivalent does not affect the anti-inflammatory activity adversely.
Claim 23
Dependent Claim
38 words
The method of claim 35 wherein the cartilage inducing factor or functional equivalent is a homodimer whose chains have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-, or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Gln-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 24
Dependent Claim
16 words
The method of claim 19 wherein the cartilage inducing factor or functional equivalent is administered topically.
References Cited (Backward Citations)
US3400199A
Cited
US4394370A
Cited
US4473551A
Cited
US4434094A
Cited
EP0128849A1
Cited
EP0169016A2
Cited
EP0269408A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-04-15 | 1994-10-15 | 1995-04-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-04-15 | 1998-10-15 | 1999-04-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-04-15 | 2002-10-15 | 2003-04-16 | $7700.00 | Window Closed / Lapsed |